Malmö-based Ascelia Pharma – previously CMC Contrast – has been shopping on the Danish side of Öresund and acquired the phase I company Oncoral.
”We have been looking very, very intensively for a drug with a low risk profile in the development phase and a desirable patient group that would give us the opportunity of developing significantly better drugs. Oncoral had it all,” says Ascelia’s Danish CEO, Magnus Corfitzen, in an interview with MedWatch.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.